GSK steps closer to new drug milestone but R&D woes ruffle investor feathers

British pharmaceutical giant GlaxoSmithKline (GSK) grew a step closer to securing its first drug approval since the split from its consumer health unit Haleon in July, but concerns over its share price remain. The US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) have agreed that the benefit of GSK’s Daprodustat…
Read More